Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day

Gabi Shemesh, Elad Moisseiev, Moshe Lazar, Shimon Kurtz

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To evaluate the safety and efficacy in intraocular pressure (IOP) reduction of increasing Cosopt dosage from twice to three times a day. Methods: The study included patients with primary open-angle glaucoma or ocular hypertension. After a washout period, IOP was measured at baseline, after 4 weeks of treatment with Cosopt twice a day, and after another 4 weeks of treatment with Cosopt three times a day. Blood pressure, heart rate, and oxygen saturation levels were also recorded. Results: Twenty-nine eyes of 29 patients were included. Increasing Cosopt dosage resulted in a statistically significant (P < 0.001) additional reduction in IOP of 2.2 ± 1.58 mmHg (10.69% ± 7.49% of the baseline IOP values). There were no local or systemic adverse effects. Conclusion: Treatment with Cosopt three times a day was more effective in reducing IOP than twice a day, with no effect on safety.

Original languageEnglish
Pages (from-to)283-287
Number of pages5
JournalClinical Ophthalmology
Volume6
Issue number1
DOIs
StatePublished - 25 Feb 2012

Keywords

  • Cosopt
  • Dorzolamide
  • Dosage
  • Glaucoma
  • Intraocular pressure
  • Timolol

Fingerprint

Dive into the research topics of 'Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day'. Together they form a unique fingerprint.

Cite this